Search Results

You are looking at 151 - 160 of 388 items for :

  • Refine by Access: All x
Clear All
Full access

Updates in the Management of Small Cell Lung Cancer

Presented by: Apar Kishor Ganti

-up.” Although PCI decreases the incidence of brain metastases, it is associated with toxicities. Acute toxicities include scalp edema, fatigue, alopecia, nausea, and vomiting; long-term toxicities such as neurologic and intellectual disabilities become more

Full access

NCCN News

, nausea and vomiting, and special considerations for adolescents and young adults across all cancer types. There are also patient guidelines devoted to detection, prevention, and risk reduction, including the latest recommendations for colorectal, lung

Full access

Management of Metastatic Prostate Cancer

Presented by: Archana Ajmera, Rana R. McKay, and Kelly L. Stratton

177 Lu-PSMA-617 improved both the objective response rate and PSA responses. “I think [one of] the biggest things to watch out for with this regimen are fatigue and myelosuppression,” she remarked. Dry mouth, nausea and vomiting, and renal effects were

Full access

Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer

Andrea Cercek, Karyn A. Goodman, Carla Hajj, Emily Weisberger, Neil H. Segal, Diane L. Reidy-Lagunes, Zsofia K. Stadler, Abraham J. Wu, Martin R. Weiser, Philip B. Paty, Jose G. Guillem, Garrett M. Nash, Larissa K. Temple, Julio Garcia-Aguilar, and Leonard B. Saltz

) The most common grade 1/2 toxicities with FOLFOX were fatigue (58%), nausea (32%), and neutropenia (25%). The most common grade 3 toxicities were diarrhea (4%), fatigue (1%), nausea (1%), and neutropenia (1%). These were managed with dose reductions

Full access

Pertuzumab in the Treatment of HER2+ Breast Cancer

Komal Jhaveri and Francisco J. Esteva

reached and pertuzumab was well tolerated, with mostly grade 1 or 2 toxicities of asthenia (62%), vomiting (52%), nausea (48%), abdominal pain (48%), rash (43%), diarrhea (43%), and anemia (33%). One event of grade 3 dose-limiting toxicity (DLT

Full access

Psychotropic and Opioid Medication Use in Older Patients With Breast Cancer Across the Care Trajectory: A Population-Based Cohort Study

Ania Syrowatka, Sue-Ling Chang, Robyn Tamblyn, Nancy E. Mayo, and Ari N. Meguerditchian

types. Best practice guidelines generally recommend avoiding antipsychotics in older populations; however, short-term use of antipsychotics is considered acceptable to manage chemotherapy-induced nausea and vomiting. 10 Given that antipsychotics were

Full access

Adolescent and Young Adult Colorectal Cancer

Joleen M. Hubbard and Axel Grothey

symptomatic at diagnosis. The most common initial symptoms were rectal bleeding (51%), change in bowel habits (18%), abdominal pain (32%), weight loss (13%), nausea/vomiting (7%), and melena (2%). Younger patients commonly experience a delay in diagnosis

Full access

Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitor–Related Esophagitis

Kavea Panneerselvam, Rajan N. Amin, Dongguang Wei, Dongfeng Tan, Phillip J. Lum, Hao Chi Zhang, David M. Richards, Mehmet Altan, Petros Grivas, John A. Thompson, Anusha S. Thomas, and Yinghong Wang

Patients underwent EGD primarily for evaluation of nausea and vomiting (33%), dysphagia (19%), or hematemesis (19%). The median time from ICI initiation to onset of endoscopic evidence of esophagitis was 4 months (interquartile range [IQR], 2–9 months

Full access

Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology

Daniel A. Pollyea, Jessica K. Altman, Rita Assi, Dale Bixby, Amir T. Fathi, James M. Foran, Ivana Gojo, Aric C. Hall, Brian A. Jonas, Ashwin Kishtagari, Jeffrey Lancet, Lori Maness, James Mangan, Gabriel Mannis, Guido Marcucci, Alice Mims, Kelsey Moriarty, Moaath Mustafa Ali, Jadee Neff, Reza Nejati, Rebecca Olin, Mary-Elizabeth Percival, Alexander Perl, Amanda Przespolewski, Dinesh Rao, Farhad Ravandi, Rory Shallis, Paul J. Shami, Eytan Stein, Richard M. Stone, Kendra Sweet, Swapna Thota, Geoffrey Uy, Pankit Vachhani, Carly J. Cassara, Deborah A. Freedman-Cass, and Katie Stehman

response was 5 months (range, 1–20+ months), with responses occurring in all sites of disease, including skin, bone marrow, and lymph nodes. Acute infusion-related adverse effects such as fever, chills, and nausea were mild to moderate in severity and were

Full access

Change Toward Healthier Lifestyles Is Associated With Better Health-Related Quality of Life in Long-Term Colorectal Cancer Survivors

Ruth Elisa Eyl-Armbruster, Melissa S.Y. Thong, Prudence R. Carr, Lina Jansen, Jenny Chang-Claude, Michael Hoffmeister, Hermann Brenner, and Volker Arndt

poorer functioning and global health/QoL and more problems with fatigue, pain, dyspnea, diarrhea, appetite loss, nausea/vomiting, and finances compared with survivors who maintained a moderate/high HLS. Figure 2. Difference in mean EORTC QLQ-C30